Additionally, we sought to compare the in vitro efficacy of these compounds in FLT3-ITD+ AML cell lines with the current standard of care compounds used for FLT3-ITD+ malignancies, including the broad spectrum chemotherapeutic cytarabine and the FDA-approved FLT3 inhibitors midostaurin and gilteritinib. Here, FLT3 is linked to acute myeloid leukemia.